Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Ringdén, Olle; Erkers, Tom; Nava, Stefano; Uzunel, Mehmet; Iwarsson, Erik; Conrad, Réka; Westgren, Magnus; Mattsson, Jonas; Kaipe, Helen

doi:10.1016/j.bbmt.2012.11.084

Cited by 23 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the patients had side effects either during or immediately after the Their results showed that there was an overall response rate of 75% [144]. The results by without an HLA-identical sibling donor was safe, effectively reduced the incidence of severe GVHD, and improved patient survival [150].…”

Section: Therapeutic Application Of Mscs For Immune Diseasesmentioning

confidence: 95%

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Zhao¹,

Ren

Han

2016

Journal of Cellular Immunotherapy

242

200

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) represent a heterogenous population of adult,fibroblast-like multi-potent cells. MSCs have drawn much attention during the last decade in the field of regenerative medicine, mainly due to their capacity to differentiate into specific cell types, abundant production of soluble growth factors and cytokines, and hematopoiesis supporting properties. In addition, MSCs can migrate to the sites of inflammation and hold potent of immunomodulatory and anti-inflammatory effects through cell and cell interactions between MSCs and lymphocytes or production of soluble factors. Therefore, the application of MSCs in many disease situations is full of possibilities for future clinical treatment. Phase III clinical trials have been run using

show abstract

Section: Therapeutic Application Of Mscs For Immune Diseasesmentioning

confidence: 95%

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Zhao¹,

Ren

Han

2016

Journal of Cellular Immunotherapy

242

200

View full text Add to dashboard Cite

show abstract

“…Also, in comparison with international data, we are managing treatment‐related toxicities with well‐directed supportive care strategies; that is, there has been reduced TRM in recent years. We introduced the treatment for severe acute GvHD with MSCs and DSCs, which has improved the outcome in our patients .…”

Section: Discussionmentioning

confidence: 99%

“…In more severe cases, ATG , methylprednisolone, MTX, psoralen, and UV light (PUVA) were used. In the P2 group, children with corticosteroid‐refractory, that is, no response after seven days of treatment or clear progression after five days, GvHD were treated with MSCs (n = 29) and more recently with DSCs (n = 8) .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation – A comparison of the last two decades

Svenberg

Remberger

Uzunel

et al. 2016

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

Pediatric protocols for allogeneic hematopoietic SCT have been altered during the last two decades. To compare the outcomes in children (<18 yr old), who underwent SCT at our center during 1992-2002 (P1) and 2003-2013 (P2). We retrospectively analyzed 188 patients in P1 and 201 patients in P2. The most significant protocol changes during P2 compared with P1 were a decrease in MAC protocols, particularly those containing TBI, an increase in RIC protocols, and altered GvHD prophylaxis. In addition, P2 had more patients with nonmalignant diagnoses (p = 0.002), more mismatched (MM) donors (p = 0.01), and more umbilical CB grafts (p = 0.03). Mesenchymal or DSCs were used for severe acute GvHD during P2. Three-yr OS in P1 was 58%, and in P2, it was 78% (p < 0.001). Improved OS was seen in both malignant disorders (51% vs. 68%; p = 0.05) and nonmalignant disorders (77% vs. 87%; p = 0.04). Multivariate analysis showed that SCT during P2 was associated with reduced mortality (HR = 0.57; p = 0.005), reduced TRM (HR = 0.57; p = 0.03), unchanged relapse rate, similar rate of GF, less chronic GvHD (HR = 0.49; p = 0.01), and more acute GvHD (HR = 1.77, p = 0.007). During recent years, OS has improved at our center, possibly reflecting the introduction of less toxic conditioning regimens and a number of other methodological developments in SCT.

show abstract

“…The potential of MSCs to treat GvHD was first illustrated by the transplantation of haploidentical MSCs in a patient with refractory grade IV aGvHD of the gut and liver, a potential that was confirmed in a Phase II study involving 55 patients [205,206]. It is worth noting here that beyond MSCs derived from bone marrow, other cell populations have already shown promises including fetal membrane stromal cells derived from the placenta for end-stage aGvHD [207]. In addition, it is important to note that several clinical trials using MSCs for GvHD have demonstrated varied survival outcomes and not delivered on this potential as exemplified by long-term results attained using bone-marrow-derived MSCs for severe aGvHD where the observed survival rates were not particularly promising, with death from infection being common in MSC-treated patients (n = 31) [208].…”

Section: Mscs In Gvhdmentioning

confidence: 95%

The Potential of Cytotherapeutics in Hematologic Reconstitution and in the Treatment and Prophylaxis of Graft-Versus-Host Disease. Chapter II: Emerging Transformational Cytotherapies

Vertès

2015

Regen. Med.

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for inherited anemias, immunodeficiencies or hematologic malignancies. A major complication of allo-HSCT associated with high transplant-related mortality rates is graft-versus-host disease (GvHD). Current and future clinical benefits in HSCT enabled by advances in hematopoietic stem cells, mesenchymal stem cells, Tregs and natural killer cells technologies are reviewed here and discussed. Among these evolutions, based on the need for mesenchymal stem cells to be recruited by an inflammatory environment, the development and use of novel GvHD biomarkers could be explored further to deliver the right pharmaceutical to the right patient at the right time. The successful commercialization of cytotherapeutics to efficiently manage GvHD will create a virtuous 'halo' effect for regenerative medicine.

show abstract

Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Cited by 23 publications

References 0 publications

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation – A comparison of the last two decades

The Potential of Cytotherapeutics in Hematologic Reconstitution and in the Treatment and Prophylaxis of Graft-Versus-Host Disease. Chapter II: Emerging Transformational Cytotherapies

Contact Info

Product

Resources

About